It appears that your browser may be outdated and performance may be limited. The My Study builder is best viewed with the latest internet browsers. However, if you’d prefer to use our standard form, you can access it below.

Go to Internet Explorer Quick Quote Form

Dismiss this message

Salivary Estradiol ELISA Kit

Technical Summary

Assay Protocol
Rev. 09.15.16
Specifications
Catalog#: 1-3702
Format: 96-well plate
Assay Time: ~ 3 hrs
Sample Volume/Test: 100 µL
Sensitivity: 0.1 pg/mL
Assay Range: 1 pg/mL - 32 pg/mL
Storage Requirements: 2-8°C
Tests Per Kit
Singlet: 76
Duplicate: 38
Target Analyte
Technical Documentation

Salivary Estradiol Assay Kit Overview

Intended Use

The Salimetrics 17β-Estradiol Enzyme Immunoassay Kit is a competitive immunoassay specifically designed and validated for the quantitative measurement of salivary Estradiol. It is not intended for diagnostic use. It is intended only for research use in humans and some animals. Salimetrics has not validated this kit for serum or plasma samples.

Introduction

Estradiol (17β-Estradiol, E2, 1,3,5(10)-estratriene-3, 17β-diol), a steroid hormone, is produced primarily by the ovarian follicles from testosterone. Estradiol is the most active naturally secreted estrogen. In men, Estradiol originates in the testes and from extraglandular conversion of androgens. Circulating Estradiol levels are relatively high at birth in both males and females, but decrease postnatally. In prepubertal children and men, levels are non-cyclic and low. During puberty, there are gradual increases in Estradiol levels in both males and females. Interactions between luteinizing hormone (LH) and follicle-stimulating hormone (FSH) cause the release of Estradiol from the ovaries in premenopausal women. Estradiol secretion is low in postmenopausal women. Research concerning Estradiol has focused predominantly on reproductive issues such as conception, ovulation, infertility, and menopause. Yet, Estradiol affects a diversity of biological processes involved with reproductive capacity, establishment and maintenance of pregnancy, parenting, coronary artery disease, immunocompetence, cancer susceptibility, and neuroprotection. Estradiol is also believed to affect individual differences in cognitive and socioemotional processes as well as psychopathology. Estrogens have been measured by many immunoassay methods. Studies suggest that Estradiol can be accurately measured in saliva.

Salivary Estradiol Assay Principle

This is a competitive immunoassay kit. Estradiol in standards and samples compete with Estradiol conjugated to horseradish peroxidase for the antibody binding sites on a microtitre plate. After incubation, unbound components are washed away. Bound Estradiol Enzyme Conjugate is measured by the reaction of the horseradish peroxidase enzyme to the substrate tetramethylbenzidine (TMB). This reaction produces a blue color. A yellow color is formed after stopping the reaction with an acidic solution. The optical density is read on a standard plate reader at 450 nm. The amount of Estradiol Enzyme Conjugate detected is inversely proportional to the amount of Estradiol present in the sample.

References & Salivary Estradiol Research

    1. Abraham, G.E. (1975). The applications of steroid radioimmunoassay to gynecologic endocrinology. In: Taymor, M.L. and Green, T.H. (eds.): Progress in gynecology, Vol. 1, 111-144. New York: Grune and Stratton.
    2. Faiman, C., Winter, S.D., & Reyes, F.I. (1976). Patterns of gonadotropins and gonadal steroids throughout life. Clin Obstet Gynecol, 3(3), 467-483.
    3. Kirschner, M.A., Schneider, G., Ertel, N.H., Worton, E. (1982).  Obesity, androgens, estrogens, and cancer risk.  Cancer Res, 42 (8 suppl), 3281s-3285s.
    4. Labrie, F., Bélanger, A., Cusan, L., Candas, B. (1997).  Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: Intracrinology.  J Clin Endocrinol Metab, 82(8), 2403-9.
    5. Lipson, S.F., & Ellison, P.T. (1996). Comparison of salivary steroid profiles in naturally occurring conception and non-conception cycles. Hum Reprod, 11(10), 2090-96.
    6. Choe, J.K., Khan-Dawood, F.S., Dawood, M.Y. (1982). Progesterone and estradiol in saliva and plasma during the menstrual cycle. Am J Obstet Gynecol, 146, 557-62.
    7. Bao, A.-M., Liu, R.-Y., van Someren, E.J., et al. (2003).  Diurnal rhythm of free estradiol during the menstrual cycle.  Eur J Endocrinol, 148(2), 227-32.
    8. Chang, R.J., Plouffe Jr., L. Schaffer, K.  Physiology of the menopause. In: Comprehensive management of menopause, Lorrain, J., Flouffe Jr., L., Ravnikar, V., Speroff, L., Watts, N., eds.  New York: Springer, 1993.
    9. Reed, M.J., Lai, L.C., Owen, A.M., et al. (1990).  Effect of treatment with 4-hydroxyandrostenedione on the peripheral conversion of androstenedione to estrone and in vitro tumor aromatase activity in postmenopausal women with breast cancer.  Cancer Res, 50(1), 193-96.
    10. Shirtcliff, E.A., Dahl, R.E., Pollak, S.D. (2009). Pubertal development: Correspondence between hormonal and physical development.  Child Dev, 80(2), 327-37.

    1. Simpson, E.R. (2000). Role of aromatase in sex steroid action.  J Mol Endocrinol, 25(2), 149-56.
    2. Winters, S.J., Troen, P. (1986).  Testosterone and estradiol are co-secreted episodically by the human testis.  J Clin Invest, 78(4), 870-73.
    3. Nankin, H.R., Pinto, R., Fan, D.-F., Troen, P. (1975).  Daytime titers of testosterone, LH, estrone, estradiol, and testosterone-binding protein: Acute effects of LH and LH-releasing hormone in men.  J Clin Endocrinol Metab, 41(2), 271-81.
    4. Ouyang, P., Michos, E.D., Kara, R.H. (2006). Hormone replacement therapy and the cardiovascular system: Lessons learned and unanswered questions.  J Am College Cardiol, 47(9), 1741-53.
    5. McCarthy, M.M. (2008). Estradiol and the developing brain. Physiol Rev, 88(1), 91-134.
    6. Balthazart, J., Cornil, C.A., Taziaux, M., et al. (2006). Rapid changes in production and behavioral action of estrogens. Neuroscience, 138(3), 783-91.
    7. Karpuzoglu, E., Ahmed, S.A. (2006).  Estrogen regulation of nitric oxide and inducible nitric oxide synthase (iNOS) in immune cells: Implications for immunity, autoimmune diseases, and apoptosis.  Nitric Oxide, 15(3), 177-86.
    8. Colditz, G. A. 1998.  Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J Natl Cancer Inst, 90(11), 814-23.
    9. Lépine, J., Audet-Walsh, E., Grégoire, J., et al. (2010)  Circulating estrogens in endometrial cancer cases and their relationship with tissular expression of key estrogen biosynthesis and metabolic pathways.  J Clin Endocinol Metab, 95(6), 2689-98.
    10. Sasano, H., Harada, N. (1998). Intratumoral aromatase in human breast, endometrial, and ovarian malilgnancies.  Endocr  Rev, 19(5), 593-607.
    11. Vining, R.F., & McGinley, R.A. (1987). The measurement of hormones in saliva: Possibilities and pitfalls. J Steroid Biochem, 27(1-3), 81-94.
    12. Choe, J.K., Khan-Dawood, F.S., & Dawood, M.Y. (1983). Progesterone and estradiol in saliva and plasma during the menstrual cycle. Am J Obstet Gynecol, 147(5), 557-62.
    13. Shirtcliff, E.A., Granger, D.A., Schwartz, E.B., et al. (2000). Assessing estradiol in biobehavioral studies using saliva and blood spots: Simple radioimmunoassay protocols, reliability, and comparative validity. Horm Behav, 38(2), 137-47.
    14. Ellison, P.T., Lipson, S.F. (1999). Salivary estradiol–A viable alternative? Fertil Steril, 72(5), 951-52.)